Brainstorm Cell Therapeutics Q3 2026 Results: Net Loss of $1.73M, Loss Narrows
BrainStorm Cell Therapeutics reported a net loss of $7.7 million for the nine months ended September 30, 2026, compared to $7.9 million in the prior year period. The company faces a significant stockholders' deficit of $12.3 million and maintains a very low cash position of $163 thousand, relying on private placements and short-term loans to fund operations.
- Key figure
- Net loss $1.73M